The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2)

PURPOSE: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas. PATIENTS AND METHODS: Sixteen U.S....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A., Haura, Eric, Politi, Katerina, Glisson, Bonnie, Cetnar, Jeremy, Garon, Edward B., Schiller, Joan, Waqar, Saiama N., Sequist, Lecia V., Brahmer, Julie, Shyr, Yu, Kugler, Kelly, Wistuba, Ignacio I., Johnson, Bruce E., Minna, John D., Kris, Mark G., Bunn, Paul A., Kwiatkowski, David J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7008001/
https://ncbi.nlm.nih.gov/pubmed/29217530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados